Breaking News
Investing Pro 0
Cyber Monday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER

Alzheimer's drug study yields positive results, say makers Eisai and Biogen

Stock Markets Sep 29, 2022 04:17AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. An Alzheimer's patient rests on a bench after a walk at the Village Landais Alzheimer site in Dax, France, September 24, 2020. Picture taken on September 24, 2020. REUTERS/Gonzalo Fuentes/File Photo 2/2
 
LLY
-0.80%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
BIIB
-0.44%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ESALY
-0.41%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Deena Beasley, Julie Steenhuysen and Rocky Swift

(Reuters) - An experimental Alzheimer's drug made by Eisai Co (OTC:ESALY) Ltd and Biogen (NASDAQ:BIIB) slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.

Multiple drugmakers have so far tried and failed to find an effective treatment for the brain-wasting disease that affects about 55 million people globally. A breakthrough would be a major boost to similar studies being run by Roche and Eli Lilly (NYSE:LLY).

Speaking of the Eisai-Biogen drug results announced late on Tuesday night, Ronald Petersen, director of the Mayo Clinic Alzheimer's Disease Research Center in Rochester, Minnesota said: "It's not a huge effect, but it's a positive effect".

The drug, lecanemab, slowed progress of the disease by 27% compared with a placebo, meeting the study's main goal, and potentially offering hope for patients and their families desperate for an effective treatment.

The race to stem the progression of Alzheimer's comes as the number of Americans living with the disease is expected to roughly double to 13 million by 2050, according to the Alzheimer's Association.

Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said.

Eisai, leader of the 50-50 partnership's lecanemab program, is seeking FDA approval under an accelerated pathway, with a decision expected in early January.

It is aiming for full approval and commercialization of the drug in the United States, Europe, and Japan by the end of 2023, CEO Haruo Naito told reporters in Tokyo.

After being untraded with a glut of buy orders on Wednesday, Eisai's shares, as per Tokyo stock exchange rules, closed up by their daily limit of 1,000 yen, a 17% rise, pointing to further strong buying demand on Thursday. Biogen shares surged 50% in premarket trading, lifting the stocks of rivals Roche and Eli Lilly.

Eisai said results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease.

The data is an "unequivocal win" for Alzheimer's patients, said BMO analyst Evan Seigerman while Jefferies analyst Michael Yee said it suggested a potentially new multi-billion dollar franchise.

'VERY EARLY DAYS'

Lecanemab, like the partners' previous drug Aduhelm, is an intravenous antibody designed to remove amyloid deposits. Unlike Aduhelm, lecanemab targets forms of amyloid that have not yet clumped together.

"If you can slow a disease by almost 30% that's fantastic," said Dr Jeff Cummings, director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada Las Vegas.

The so-called amyloid hypothesis has been challenged by some scientists, particularly after the U.S. Food and Drug Administration's controversial approval of Aduhelm in 2021 based on its plaque-clearing ability rather than proof that it helped slow cognitive decline. The decision came after the FDA's own panel of outside experts had advised against approval.

While the top-line results for lecanemab are convincing, it's still "very early days" in determining whether the effects are clinically meaningful, said Dr Kristian Steen Frederiksen, director of a clinical trial unit at the University of Copenhagen.

Alzheimer's "is an extremely complex disease and amyloid-related pathology is unlikely to be the only player," he said. "Therefore targeting a single target is not likely to produce large effect sizes."

Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry.

Patient advocacy groups hailed the news of positive lecanemab trial results.

"I would hope that the FDA approves the drug in January," USAgainstAlzheimer's Chairman George Vradenburg said.

The Phase III trial evaluated the drug's ability to reduce cognitive and functional decline based on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), a numerical scale used to quantify the severity of dementia in patients in areas such as memory, orientation, judgment and problem solving and personal care.

BRAIN SWELLING

The rate of a brain swelling side effect associated with anti-amyloid treatments was 12.5% in the lecanemab group, versus 1.7% in the placebo group. But many cases did not cause symptoms, with symptomatic brain swelling seen in 2.8% of those in the lecanemab group, the companies said.

Micro hemorrhages in the brain occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group.

Petersen said the side effect rate was much less than with Aduhelm and "certainly tolerable."

Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.

The controversy and reluctance by some payers to cover Aduhelm led Biogen to slash the drug's price to $28,000 per year from an initial $56,000.

Medicare, the U.S. government health plan for people 65 and older, said this year it would only pay for Aduhelm and other similar drugs if patients were enrolled in a valid clinical trial, which sharply curtailed the medication's use.

Michael Irizarry, Eisai's deputy chief clinical officer, said on a conference call that the company will have discussions with Medicare about coverage of lecanemab.

Alzheimer's drug study yields positive results, say makers Eisai and Biogen
 

Related Articles

S&P 500 slips as Apple-led dent in tech bites
S&P 500 slips as Apple-led dent in tech bites By Investing.com - Nov 29, 2022

By Yasin Ebrahim Investing.com -- The S&P 500 struggled for direction Tuesday as an Apple-infused stumble weighed on tech just as Treasury yields continue to rise amid data showing...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Sakina Axelrod
Sakina Axelrod Sep 28, 2022 2:18AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
My husband first experienced confusion and loss of memory in March of 2000 while undergoing rehab for alcoholism. Being home seemed to help him until 2006 when he gradually began experiencing Alzheimer’s symptoms. He had four to five hours a day where he wants to get a "greyhound" to "go home." Also, he thinks I am his sister and believes he has rented a car (he hasn't driven in five to 10 years). His personal hygiene was in the tank — it was necessary for him to change two to three times a day.  Without long-term insurance for his care, it was becoming stressful to care from him. this year our family doctor introduced and started him on Healthherbsclinic Alzheimer’s Disease Herbal Tincture, 6 months into treatment he improved dramatically. At the end of the full treatment course, the disease is totally under control.Visit Health Herbs Clinic website www. healthherbsclinic .com
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email